Shares of Genmab A/S (OTCMKTS:GNMSF) crossed below its 200-day moving average during trading on Tuesday . The stock has a 200-day moving average of $217.48 and traded as low as $173.79. Genmab A/S shares last traded at $173.79, with a volume of 338 shares trading hands.
Separately, ValuEngine raised Genmab A/S from a “sell” rating to a “hold” rating in a research report on Friday, March 13th.
The business’s fifty day moving average is $221.55 and its 200-day moving average is $217.30. The firm has a market cap of $11.89 billion, a PE ratio of 38.24 and a beta of 0.20. The company has a debt-to-equity ratio of 0.01, a current ratio of 14.88 and a quick ratio of 18.72.
About Genmab A/S (OTCMKTS:GNMSF)
Genmab A/S, a biotechnology company, develops antibody therapeutics for the treatment of cancer primarily in Denmark. The company markets DARZALEX, a human IgG1k monoclonal antibody for the treatment of patients with multiple myeloma (MM); and Arzerra, a human IgG1k monoclonal antibody for the treatment of chronic lymphocytic leukemia (CLL).
Featured Story: How Do I Invest in Dividend Stocks
Receive News & Ratings for Genmab A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genmab A/S and related companies with MarketBeat.com's FREE daily email newsletter.